Aortic valve replacement vs. conservative treatment in asymptomatic severe aortic stenosis: long-term follow-up of the AVATAR trial

• Published in: European heart journal Vol. 45; no. 42; pp. 4526 - 4535
• Main Authors: Banovic, Marko, Putnik, Svetozar, Da Costa, Bruno R, Penicka, Martin, Deja, Marek A, Kotrc, Martin, Kockova, Radka, Glaveckaite, Sigita, Gasparovic, Hrvoje, Pavlovic, Nikola, Velicki, Lazar, Salizzoni, Stefano, Wojakowski, Wojtek, Van Camp, Guy, Gradinac, Sinisa, Laufer, Michael, Tomovic, Sara, Busic, Ivan, Bojanic, Milica, Ristic, Arsen, Klasnja, Andrea, Matkovic, Milos, Boskovic, Nikola, Zivic, Katarina, Jovanovic, Miodrag, Nikolic, Serge D, Iung, Bernard, Bartunek, Jozef
• Format: Journal Article
• Language: English
• Published: UK Oxford University Press 08.11.2024
• Subjects: Aged; Aortic Valve - surgery; Aortic Valve Stenosis - mortality; Aortic Valve Stenosis - surgery; Aortic Valve Stenosis - therapy; Asymptomatic Diseases - therapy; Avatar; Conservative Treatment - methods; Female; Follow-Up Studies; Heart Valve Prosthesis Implantation - methods; Hospitalization - statistics & numerical data; Humans; Male; Middle Aged; Stroke; Stroke Volume - physiology; Treatment Outcome; Watchful Waiting; Aortic stenosis; Asymptomatic; Treatment; Low-risk; Outcomes; Aortic valve surgery
• ISSN: 0195-668X; 1522-9645; 1522-9645
• DOI: 10.1093/eurheartj/ehae585

Abstract Background and Aims The question of when and how to treat truly asymptomatic patients with severe aortic stenosis (AS) and normal left ventricular (LV) systolic function is still subject to debate and ongoing research. Here, the results of extended follow-up of the AVATAR trial are reported (NCT02436655, ClinicalTrials.gov). Methods The AVATAR trial randomly assigned patients with severe, asymptomatic AS and LV ejection fraction ≥ 50% to undergo either early surgical aortic valve replacement (AVR) or conservative treatment with watchful waiting strategy. All patients had negative exercise stress testing. The primary hypothesis was that early AVR will reduce a primary composite endpoint comprising all-cause death, acute myocardial infarction, stroke, or unplanned hospitalization for heart failure (HF), as compared with conservative treatment strategy. Results A total of 157 low-risk patients (mean age 67 years, 57% men, mean Society of Thoracic Surgeons score 1.7%) were randomly allocated to either the early AVR group (n = 78) or the conservative treatment group (n = 79). In an intention-to-treat analysis, after a median follow-up of 63 months, the primary composite endpoint outcome event occurred in 18/78 patients (23.1%) in the early surgery group and in 37/79 patients (46.8%) in the conservative treatment group [hazard ratio (HR) early surgery vs. conservative treatment 0.42; 95% confidence interval (CI) 0.24–0.73, P = .002]. The Kaplan–Meier estimates for individual endpoints of all-cause death and HF hospitalization were significantly lower in the early surgery compared with the conservative group (HR 0.44; 95% CI 0.23–0.85, P = .012, for all-cause death and HR 0.21; 95% CI 0.06–0.73, P = .007, for HF hospitalizations). Conclusions The extended follow-up of the AVATAR trial demonstrates better clinical outcomes with early surgical AVR in truly asymptomatic patients with severe AS and normal LV ejection fraction compared with patients treated with conservative management on watchful waiting. Structured Graphical Abstract Structured Graphical Abstract The design and main result of the AVATAR randomized trial (intention-to-treat population). AMI, acute myocardial infarction; CI, confidence interval; HF, heart failure; HR, hazard ratio; LV, left ventricular.